BrainTalk | An Inside Look at Cassava's Experimental Alzheimer's Drug with Remi Barbier

Being Patient speaks with President and CEO of Cassava Sciences Remi Barbier about the company's development of an investigational Alzheimer's drug called simufilam, and how scientists are diversifying their approach in finding an effective treatment for the disease.
We rely on donations to bring you the latest research on dementia and brain health and to support our amazing team of independent journalists. Please consider donating to support of our mission of giving people impacted by dementia a better resource and connection to experts at the forefront of research. Our audience has grown so rapidly; we have exciting plans for the future to enhance our coverage even further but we need your help. Please consider making a contribution to help fund Being Patient's editorial costs.
beingpatient.nationbuilder.com/​ (gate.sc/?url=h...)
---------------------------------------------------------------------------------------------------------------
Stay connected on social media:
To catch our Brain Talks live, join our Facebook page:
beingpatient​ (gate.sc/?url=h...) ...
To learn more about us, follow us on Instagram:
@beingpatientvoices ( / beingpatientvoices )
For the latest news on dementia research and lifestyle tips, visit our site:
www.beingpatient.com/ (gate.sc/?url=h...)

[@JimConnelley]

Recorded in 2021. The P3 trials have completed enrollment since then.

[@frankmeyers7304]

I would like to hear more about this drug. When will it be approved?

[@Mark...]

Looking at 2025 at the earliest

[@spiritjourneyme]

The final results of the phase 3 clinical trials is Nov. 2024 unless they get accelerated approval, which is very likely. It is an amazing drug!

[@sungpyon4595]

Did your mom complete phase 3 trial?

[@HTub-bo2yl]

Looks like preclinical is key